TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

15.31 Drugs for parasitic infections. Treat Guidel Med Lett 2007;5(suppl.):1-15. 16A.1 Drugs for parasitic infections. Treat Guidel Med Lett 2007;5(suppl.):1-15. 16A.2 van den Enden E. Pharmacotherapy of helminth infection. Expert Opin Pharmacother 2009;10:435- 51. 16A.3 Horton J. Albendazole: a review of anthelminthic efficacy and safety in humans. Parasitology 2000; 121(suppl. 1):S113-32. 16A.4 Cui L et al. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009;7:999-1013. 16A.5 Ashley EA et al. Artemisinin-based combinations. Curr Opin Infect Dis 2005;18:531-6. 16A.6 Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 2000;9:1815- 27. 16A.7 Adjei GO et al. Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children. Expert Rev Anti Infect Ther 2009;7:669-81. 16A.8 Cui L et al. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther 2009;7:999-1013. 16A.9 Ashley EA et al. Artemisinin-based combinations. Curr Opin Infect Dis 2005;18:531-6. 16A.10 Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs 2000;9:1815- 27. 16A.11 Patel SN et al. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti Infect Ther 2005;3:849-61. 16A.12 Pappaioanou M et al. Antibody response to pre-exposure human diploid cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986;314:280-4. 16A.13 Lefkove B et al. Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors. Expert Rev Anti Infect Ther 2007;5:573-9. 16A.14 Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008;31:91-8. 16A.15 Dourmishev AL et al. Ivermectin: pharmacology and application in dermatology. Int J Dermatol 2005; 44:981-8. 16A.16 Omura S et al. The life and times of ivermectin. A success story. Nat Rev Microbiol 2004;2:984-9. 16A.17 Thakur CP. Sodium antimony gluconate, amphotericin and myocardial damage. Lancet 1998;351: 1928-9. 16A.18 Soto J et al. Miltefosine: an oral treatment of leishmaniasis. Expert Rev Anti Infect Ther 2006;4:177- 85. 16A.19 Anderson VR et al. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;67:1947-67. 16A.20 White AC. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther 2004;2:43-50. 16A.21 Fox LM et al. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005;40:1173-80. 16A.22 Doenhoff MJ et al. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008;21:659-67. 16A.23 Cioli D et al. Praziquantel. Parasitol Res 2003;90(suppl. 1):S3-9. 16A.24 Berman J. Toxicity of commonly used antimalarial drugs. Travel Med Infect Dis 2004;2:171-84. 16A.25 White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007;7:549-58. 16A.26 Taylor WR et al. Antimalarial drug toxicity: a review. Drug Saf 2004;27:25-61. 16B.1 Demirovic JA et al. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009;66:642-8. 16B.2 Levey AS et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70. 18.1 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://aidsinfo. nih.gov/content files/AdultandAdolescentGL.pdf. Accessed on August 18th 2010. 18.2 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Tables Available at: http:// aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed on August 18 th 2010. 18.3 European AIDS Clinical Society. Guidelines: clinical management and treatment of HIV infected adults in Europe. Available at: http://www.europeanaidsclinicalsociety.org/guidelines pdf/1_Treatment _of_HIV_Infected_Adults.pdf. Accessed on August 18 th 2010. 18.4 European AIDS Clinical Society. Guidelines: prevention and management of non-infectious comorbidities in HIV. Available at: http://www.europeanaidsclinicalsociety.org/guidelinespdf/ 2_Non_Infectious _Co_Morbidities_in_HIV.pdf. Accessed on August 18 th 2010. 18.5 Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608. 18.6 Aberg JA et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009;49:651-81. 18.7 Yeni P. Prise en charge médicale des personnes infectées par le VIH. Available at: http://lesrap ports.ladocumentationfrancaise.fr/BRP/084000593/0000.pdf. Accessed on August 18 th 2010. 18.8 Hammer SM et al. Antiretroviral treatment of adult HIV infection. 2008 recommendations of the International AIDS Society - USA Panel. J Am Med Assoc 2008;300:555-70. 18.9 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1- 207. 18.10 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov/contentfiles/ PediatricGuidelines.pdf. Accessed on August 18 th 2010. 18.11 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Tables. Available at: http://aidsinfo.nih.gov/con tentfiles/Ped_Tables.pdf Accessed on August 18 th 2010.
18.12 Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Managing complications of HIV infection in HIV-infected children on antiretroviral therapy. Available at: http://aidsinfo. nih.gov/contentfiles/PediatricGL_SupII.pdf. Accesssed on August 18 th 2010. 18.13 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009; 58(RR-11):1-167. 18.14 McKellar MS et al. Pediatric HIV infection: the state of antiretroviral therapy. Expert Rev Anti Infect Ther 2008;6:167-80. 18.15 Patel K et al. Long-Term effects of highly active antiretroviral therapy on CD4 + cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008;46:1751-60. 18.16 Hammer SM. Management of newly diagnosed HIV infection. N Engl J Med 2005;353:1702-10. 18.17 Deeks SG. Antiretroviral treatment of HIV infected adults. Br Med J 2006;332:1498-93. 18.18 Huang L et al. Intensive care of patients with HIV infection. N Engl J Med 2006;355:173-81. 18.19 Branson BM. State of the art for diagnosis of HIV infection. Clin Infect Dis 2007;45(suppl. 4):S221- 5. 18.20 Lubinski C et al. HIV Policy: The path forward - a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis 2009;48:1335-44. 18.21 Deeks SG et al. HIV infection, antiretroviral treatment, ageing and non-AIDS related morbidity. Br Med J 2009;338:288-92. 18.22 Simon V et al. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet Infect Dis 2006;368:489-504. 18.23 Giordano TP et al. Retention in care: a challenge to survival with HIV infection. Clin Infect Dis 2007; 4:1493-9. 18.24 Ford N et al. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. Lancet 2009;374:2064-71. 18.25 Tuldràand A et al. Interventions to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31(suppl. 3):S154-7. 18.26 Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000;30(suppl. 2):S171-6. 18.27 Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-41. 18.28 Gulick RM. Adherence to antiretroviral therapy: how much is enough? Clin Infect Dis 2006;43:942-4. 18.29 Lazo M et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007;45:1377-85. 18.30 García de Olalla P et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002;30:105-10. 18.31 Moore RD et al. CD4 + cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44:441-6. 18.32 Kassutto S et al. Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection. Clin Infect Dis 2006;42:1024-31. 18.33 Battegay M et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006;6:280-7. 18.34 Vercauteren J et al. Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. AIDS Res Hum Retroviruses 2008;24: 355-62. 18.35 CASCADE Virology Collaboration. The impact of transmitted drug resistance on the natural history of HIV infection and response to first line therapy. AIDS 2006;20:21-8. 18.36 Sax PE et al. Should resistance testing be performed for treatment naïve HIV infected patients? A cost effectiveness analysis. Clin Infect Dis 2005;41:1316-23. 18.37 European HIV Drug Resistance Guidelines Panel. European HIV drug resistance guidelines. 2009 update. Available at: http://www.europeanaidsclinicalsociety.org/The%20European%20 HIV%20Drug %20Resistance%20Guidelines%202009%20Update.pdf. Accessed on August 18 th 2010. 18.38 Hirsch MS et al. antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society - USA Panel. Clin Infect Dis 2008;47:266-85. 18.39 Chen TK et al. Review of HIV antiretroviral drug resistance. Pediatr Infect Dis J 2008;27:749-52. 18.40 Gupta R et al. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008;47:712- 22. 18.41 Taylor S et al. Using HIV resistance tests in clinical practice. J Antimicrob Chemother 2009;64:218- 22. 18.42 Eron JJ. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis 2008;197(suppl. 3):S261-71. 18.43 Wensing AM et al. Prevalence of drug resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005;192:958-66. 18.44 Novak RM et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV infected, treatment naïve patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40:468-74. 18.45 Gupta RK et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009;9:409-17. 18.46 Ivanovic J et al. Therapeutic drug monitoring in the management of HIV-infected patients. Curr Med Chem 2008;15:1925-39. 18.47 Wertheimer BZ et al. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials 2006;7:59-69. 18.48 Fraaijj PL et al. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit 2004;26: 122-6. 18.49 Gerber JG et al. Therapeutic drug monitoring in the treatment of HIV-infection. J Clin Virol 2003;27: 117-28. 18.50 Fidler S et al. Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis 2008;21:4-10. 18.51 Zetola NM et al. Diagnosis and management of acute HIV infection. Infect Dis Clin North Am 2007; 21:19-48.
Page 1 and 2:
TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4:
1.89 Laupland KB. Vascular and para
Page 5 and 6:
of NICE guidance. Br Med J 2008;337
Page 7 and 8:
tions à Clostridium difficile dans
Page 9 and 10:
sis of placebo-controlled trials. C
Page 11 and 12:
1.446 Centers for Disease Control a
Page 13 and 14:
1.532 Olaison L et al. Enterococcal
Page 15 and 16:
1.615 Muder RR et al. Isolation of
Page 17 and 18:
2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20:
2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45 and 46: Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48: 7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71: 14B.4 Checkley AM et al. Eosinophil
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99 and 100: mortality after kidney transplantat
Page 101 and 102: 33A.1 Kearney BP et al. The penetra
Page 103 and 104: Clin Plast Surg Clinics in Plastic
Page 105 and 106: Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?